128 related articles for article (PubMed ID: 11172537)
1. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide, a therapeutic agent for APL.
Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
[TBL] [Abstract][Full Text] [Related]
3. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693
[TBL] [Abstract][Full Text] [Related]
4. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
[TBL] [Abstract][Full Text] [Related]
5. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As
Huang X; Yang Y; Zhu D; Zhao Y; Wei M; Li K; Zhu HH; Zheng X
Cell Mol Life Sci; 2022 May; 79(6):319. PubMed ID: 35622143
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia.
Lallemand-Breitenbach V; Guillemin MC; Janin A; Daniel MT; Degos L; Kogan SC; Bishop JM; de Thé H
J Exp Med; 1999 Apr; 189(7):1043-52. PubMed ID: 10190895
[TBL] [Abstract][Full Text] [Related]
7. miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
Li H; Hou J; Fu Y; Zhao Y; Liu J; Guo D; Lei R; Wu Y; Tang L; Fan S
Ann Hematol; 2023 Dec; 102(12):3357-3367. PubMed ID: 37726492
[TBL] [Abstract][Full Text] [Related]
8. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
[TBL] [Abstract][Full Text] [Related]
9. Gelling Bodies: Understanding the Mechanisms Underlying Arsenic Trioxide Action.
Salomoni P
Cancer Discov; 2023 Dec; 13(12):2505-2506. PubMed ID: 38084094
[TBL] [Abstract][Full Text] [Related]
10. Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia.
Moosavi MA; Djavaheri-Mergny M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330838
[TBL] [Abstract][Full Text] [Related]
11. Pyrrolidine Dithiocarbamate Enhances the Cytotoxic Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia Cells.
Yu S; Ge Z; Chen W; Han J
Comb Chem High Throughput Screen; 2023; 26(11):2067-2076. PubMed ID: 36694317
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
Bercier P; Wang QQ; Zang N; Zhang J; Yang C; Maimaitiyiming Y; Abou-Ghali M; Berthier C; Wu C; Niwa-Kawakita M; Dirami T; Geoffroy MC; Ferhi O; Quentin S; Benhenda S; Ogra Y; Gueroui Z; Zhou C; Naranmandura H; de Thé H; Lallemand-Breitenbach V
Cancer Discov; 2023 Dec; 13(12):2548-2565. PubMed ID: 37655965
[TBL] [Abstract][Full Text] [Related]
13. Metabolism, toxicity and anticancer activities of arsenic compounds.
Khairul I; Wang QQ; Jiang YH; Wang C; Naranmandura H
Oncotarget; 2017 Apr; 8(14):23905-23926. PubMed ID: 28108741
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins.
Maimaitiyiming Y; Wang QQ; Yang C; Ogra Y; Lou Y; Smith CA; Hussain L; Shao YM; Lin J; Liu J; Wang L; Zhu Y; Lou H; Huang Y; Li X; Chang KJ; Chen H; Li H; Huang Y; Tse E; Sun J; Bu N; Chiou SH; Zhang YF; Hua HY; Ma LY; Huang P; Ge MH; Cao FL; Cheng X; Sun H; Zhou J; Vasliou V; Xu P; Jin J; Bjorklund M; Zhu HH; Hsu CH; Naranmandura H
Blood Cancer Discov; 2021 Jul; 2(4):388-401. PubMed ID: 34661159
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.
Swindell EP; Hankins PL; Chen H; Miodragović DU; O'Halloran TV
Inorg Chem; 2013 Nov; 52(21):12292-304. PubMed ID: 24147771
[TBL] [Abstract][Full Text] [Related]
16. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite.
Liu J; Lu Y; Wu Q; Goyer RA; Waalkes MP
J Pharmacol Exp Ther; 2008 Aug; 326(2):363-8. PubMed ID: 18463319
[TBL] [Abstract][Full Text] [Related]
17. Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology.
Dawood M; Hamdoun S; Efferth T
Front Pharmacol; 2018; 9():143. PubMed ID: 29535630
[TBL] [Abstract][Full Text] [Related]
18. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.
Chen SJ; Zhou GB; Zhang XW; Mao JH; de Thé H; Chen Z
Blood; 2011 Jun; 117(24):6425-37. PubMed ID: 21422471
[TBL] [Abstract][Full Text] [Related]
19. No Association of AS3MT Gene Polymorphisms with Susceptibility to Hepatotoxicity in APL Patients Treated with AS2O3: A Single-Center Study.
Joneidi Z; Mortazavi Y; Chahardouli B; Rostami S; Vaezi M; Nabipour M; Biglari A; Ghavamzadeh A
Int J Hematol Oncol Stem Cell Res; 2023 Oct; 17(4):281-290. PubMed ID: 38076777
[No Abstract] [Full Text] [Related]
20. Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report.
Emmons GS; Steingart RH; Stewart JA; Mertens WC
J Med Case Rep; 2012 Oct; 6():355. PubMed ID: 23078653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
